Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes
December 2020
You'll start to see more patients withOUT diabetes using SGLT2 inhibitors (Invokana, etc)...for heart failure or kidney disease.
That's because growing evidence suggests these meds may improve outcomes when added to standard therapy.
In heart failure with reduced ejection fraction (HFrEF), adding Jardiance (empagliflozin) over 16 months prevents hospitalization or CV death in about 1 in 14 type 2s...or 1 in 26 patients withOUT diabetes.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote